Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.28 | 0.51 | -3.75 | -0.01 |
| FCF Yield | -6.43% | -6.69% | -8.51% | -4.99% |
| EV / EBITDA | -18.93 | -10.72 | -10.48 | -13.73 |
| Quality | ||||
| ROIC | -26.04% | -26.10% | -39.30% | -27.13% |
| Gross Margin | 93.62% | 98.11% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.93 | 0.74 | 0.88 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 73.94% | 872.10% | 7.46% | – |
| Free Cash Flow Growth | -42.56% | 35.18% | -56.62% | -254.59% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | 1.34 | 1.57 | 2.61 |
| Interest Coverage | -5.25 | -33.69 | -73.78 | -966.21 |
| Efficiency | ||||
| Inventory Turnover | 3.77 | 4.17 | 0.00 | 0.00 |
| Cash Conversion Cycle | -322.67 | -3,727.16 | 0.00 | 0.00 |